Patents by Inventor Guillaume Chevreux

Guillaume Chevreux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Factor VII composition having a substantially homogenous isoelectric point
    Patent number: 11254920
    Abstract: The present invention relates to a factor VII composition having a substantially homogeneous isoelectric point and to a method for formulating such a composition. The present invention also relates to the therapeutic use of a factor VII composition having a substantially homogeneous isoelectric point.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: February 22, 2022
    Assignee: Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventor: Guillaume Chevreux
  • Factor VII Composition Having a Substantially Homogeneous Isoelectric Point
    Publication number: 20200362329
    Abstract: The present invention relates to a factor VII composition having a substantially homogeneous isoelectric point and to a method for formulating such a composition. The present invention also relates to the therapeutic use of a factor VII composition having a substantially homogeneous isoelectric point.
    Type: Application
    Filed: May 7, 2020
    Publication date: November 19, 2020
    Applicant: Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventor: Guillaume CHEVREUX
  • Factor VII Composition Having a Substantially Homogenous Isoelectric Point
    Publication number: 20200270596
    Abstract: The present invention relates to a factor VII composition having a substantially homogeneous isoelectric point and to a method for formulating such a composition. The present invention also relates to the therapeutic use of a factor VII composition having a substantially homogeneous isoelectric point.
    Type: Application
    Filed: May 7, 2020
    Publication date: August 27, 2020
    Applicant: Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventor: Guillaume CHEVREUX
  • Transgenic factor VII having a specific N-glycosylation and substantially homogenous isoelectric point
    Patent number: 10683492
    Abstract: The present invention relates to a factor VII composition having a substantially homogeneous isoelectric point and to a method for formulating such a composition. The present invention also relates to the therapeutic use of a factor VII composition having a substantially homogeneous isoelectric point.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: June 16, 2020
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventor: Guillaume Chevreux
  • LIQUID COMPOSITION OF HUMAN ALBUMIN FOR THERAPEUTIC USE
    Publication number: 20180250368
    Abstract: Disclosed is a liquid composition of human albumin for therapeutic use, in which at least 50% of the albumin has a molecular weight of 66.438 Da, plus or minus 5 Da, preferentially plus or minus 2 Da, the composition also including a sodium salt.
    Type: Application
    Filed: September 9, 2016
    Publication date: September 6, 2018
    Inventors: Damien BATAILLE, Michel NOGRE, Guillaume CHEVREUX
  • TRANSGENIC FACTOR VII HAVING A SPECIFIC N-GLYCOSYLATION AND SUBSTANTIALLY HOMOGENOUS ISOELECTRIC POINT
    Publication number: 20160152965
    Abstract: The present invention relates to a factor VII composition having a substantially homogeneous isoelectric point and to a method for formulating such a composition. The present invention also relates to the therapeutic use of a factor VII composition having a substantially homogeneous isoelectric point.
    Type: Application
    Filed: June 10, 2014
    Publication date: June 2, 2016
    Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventor: Guillaume Chevreux
  • NOVEL MEDICAMENTS COMPRISING AN ANTIBODY COMPOSITION ENRICHED WITH PREDOMINANT CHARGE ISOFORM
    Publication number: 20160046722
    Abstract: The present invention lies in the technical field of antibody therapies involving a mechanism of target-cell destruction by ADCC. It relates to purified antibody compositions, obtained by chromatographic fractionation of the various charge isoforms naturally present in an antibody composition and combining one or more chromatographic fractions corresponding to the predominant peak of the chromatogram, the resulting monoclonal antibody composition being enriched in said predominant peak, said peak representing at least 85% of the chromatogram of the composition obtained, for use as a medicament.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 18, 2016
    Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Guillaume Chevreux, Nicolas Bihoreau
  • HIGHLY GALACTOSYLATED ANTIBODIES
    Publication number: 20140296490
    Abstract: In one aspect, the disclosure relates to antibodies that are highly galactosylated, methods of production of these antibodies and methods of use of these antibodies.
    Type: Application
    Filed: August 10, 2012
    Publication date: October 2, 2014
    Applicant: Laboratoire Français du Fractionnement et des Biotechnologies
    Inventors: Valegh Faid, Guillaume Chevreux